Rezolute, Inc. filings document regulatory disclosures for a Nasdaq-listed Nevada biopharmaceutical company developing ersodetug for hyperinsulinism. Recent Current Reports on Form 8-K include Regulation FD disclosures on the sunRIZE congenital hyperinsulinism program, FDA meeting updates, investor presentations, expanded access data in tumor hyperinsulinism, and exhibits containing related press releases and corporate materials.
The filing record also includes Form 8-K disclosures for quarterly financial results, annual stockholder voting matters, board elections and amendments to executive employment agreements. These documents record the company’s clinical-development communications, governance actions, capital-market disclosures and material corporate agreements.
Rezolute, Inc. Schedule 13G summary: This filing reports that several affiliated entities and individuals associated with Invus and Avicenna disclosed beneficial ownership of Rezolute common stock. Invus Public Equities directly holds 4,171,401 shares (about 4.6% of the class) and Avicenna Life Sci Master Fund LP directly holds 698,599 shares (about 0.8%). Combined, Mr. Raymond Debbane is disclosed as beneficial owner of 4,870,000 shares, representing 5.4% of the 90,811,368 shares outstanding used in the calculation. The filing states the positions were not acquired to change control of the issuer and lists addresses and organizational citizenship for each reporting person.
Rezolute, Inc. Schedule 13G summary: This filing reports that several affiliated entities and individuals associated with Invus and Avicenna disclosed beneficial ownership of Rezolute common stock. Invus Public Equities directly holds 4,171,401 shares (about 4.6% of the class) and Avicenna Life Sci Master Fund LP directly holds 698,599 shares (about 0.8%). Combined, Mr. Raymond Debbane is disclosed as beneficial owner of 4,870,000 shares, representing 5.4% of the 90,811,368 shares outstanding used in the calculation. The filing states the positions were not acquired to change control of the issuer and lists addresses and organizational citizenship for each reporting person.
Rezolute, Inc. reported material financing and corporate items in its Form 10-K. The company completed an underwritten offering in April 2025 that generated aggregate gross proceeds of approximately $103.5 million and net proceeds of approximately $96.8 million. During fiscal 2025 the company also completed private placements that yielded net proceeds of $4.2 million and $6.0 million in prior periods, and issued pre-funded warrants and common stock in multiple transactions.
The filing discloses license and milestone obligations, including a $5.0 million milestone paid in May 2025 under the XOMA License Agreement upon dosing in a Phase 3 trial, a $25.0 million milestone due upon regulatory approval and up to $185.0 million of additional milestone payments tied to annual net sales. The company reports significant net operating loss (NOL) carryforwards totaling approximately $201.4 million with portions subject to expiration and IRC Section 382 limitations.
Rezolute, Inc. reported material financing and corporate items in its Form 10-K. The company completed an underwritten offering in April 2025 that generated aggregate gross proceeds of approximately $103.5 million and net proceeds of approximately $96.8 million. During fiscal 2025 the company also completed private placements that yielded net proceeds of $4.2 million and $6.0 million in prior periods, and issued pre-funded warrants and common stock in multiple transactions.
The filing discloses license and milestone obligations, including a $5.0 million milestone paid in May 2025 under the XOMA License Agreement upon dosing in a Phase 3 trial, a $25.0 million milestone due upon regulatory approval and up to $185.0 million of additional milestone payments tied to annual net sales. The company reports significant net operating loss (NOL) carryforwards totaling approximately $201.4 million with portions subject to expiration and IRC Section 382 limitations.
Rezolute, Inc. reported that it has released its financial results for the fourth quarter and fiscal year ended June 30, 2025. The company shared these results through a press release dated September 17, 2025, which is referenced as an exhibit to the current report. The disclosure indicates that detailed financial figures and commentary are contained in the accompanying press release rather than in this summary document.
Rezolute, Inc. reported that it has reached alignment with the U.S. Food and Drug Administration on the design of its ongoing Phase 3 trial of Ersodetug in tumor hyperinsulinism. This means the company and the regulator are now on the same page about how the late-stage study should be run, which is an important step for advancing the program.
The company also updated its corporate presentation to incorporate new information from the upLIFT study. These materials were shared through a press release and an investor presentation that are attached as exhibits to this current report.
Rezolute, Inc. (RZLT) Form 4 shows the company granted equity to its Chief Commercial Officer, Sunil Ratilal Karnawat. On 08/18/2025 Karnawat was awarded 25,000 restricted stock units that vest in four equal annual installments beginning 09/01/2026. The filing also reports an employee stock option grant to purchase 275,000 common shares at an exercise price of $6.55 per share, exercisable under a vesting schedule beginning one year after grant and completing monthly thereafter, with an expiration on 08/18/2035. Following the reported transactions, Karnawat directly beneficially owns 27,442 common shares and indirectly holds 8,000 shares in an IRA and 1,898 shares in an HSA. The Form 4 was signed by Karnawat on 08/27/2025.
Rezolute, Inc. (RZLT) Form 3 filed for Sunil Ratilal Karnawat reports initial beneficial ownership disclosures for an officer serving as Chief Commercial Officer. The filing shows 2,442 common shares held directly, plus 8,000 common shares held indirectly in an IRA and 1,898 common shares held indirectly in a Health Savings Account, for a total of 12,340 shares reported. The filing is signed and dated by the reporting person.
Rezolute, Inc. filed an Form 8-K reporting a material corporate event under Item 5.02: the election or appointment of a Chief Commercial Officer. The filing references a press release dated August 20, 2025 and is signed by Chief Executive Officer Nevan Charles Elam. The submission also includes standard cover and interactive data references for the Inline XBRL document and cites communications rules for solicitations and pre-commencement communications under the Securities Act and Exchange Act.
The filing provides notice of an executive appointment but does not disclose the appointee's name, compensation, start date, or other background details within the provided text. No financial tables, transactions, or earnings data are included in the excerpt supplied.
Insider Trading Alert: Brian Kenneth Roberts, Chief Medical Officer of Rezolute (RZLT), has acquired 2,500 common shares at a weighted average price of $4.3756 per share on June 25, 2025. The transaction was executed through multiple purchases ranging from $4.37 to $4.38 per share.
Following this transaction, Roberts' holdings include:
- Direct ownership: 172,852 common shares (15,500 + 157,352 from previous holdings)
- Indirect ownership: 1,376 shares held by minor child
This insider purchase demonstrates continued confidence in the company by a key executive. The Form 4 filing was completed within the required reporting timeframe, with the transaction executed on June 25, 2025, and reported on June 28, 2025.
Filing overview: On 24 June 2025, Rezolute, Inc. (ticker RZLT) submitted a Form 4 disclosing a change in beneficial ownership by its Chief Financial Officer, Daron Evans.
Transaction details: Mr. Evans executed an open-market purchase (transaction code “P”) of 5,000 common shares at $4.05 per share on the reported date. No sales or other derivative transactions were listed.
Post-transaction holdings: After the purchase, the CFO directly holds 268,900 shares. He also reports indirect ownership of 23,000 shares for minor child #1, 20,000 shares held by his spouse, 4,500 shares each for minor children #2 and #3, and 40,000 shares through PoC Capital LLC, a California entity he manages. Combined, these positions represent 360,900 common shares. The filing states that Evans disclaims beneficial ownership of PoC Capital shares except for his pecuniary interest.
The Form 4 was electronically signed by Daron Evans on 24 June 2025.